Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No suprise here!! Going back up!!
A lot of people pulled profits yesterday to jump on opportunity on another biotech.
Exactly! Everyone thinks the sky is falling on the first red day after several green days. Wow!!
I don't golf, but I'll buy a couple rounds of beverages!! Lol
Yes, everyone...go look at the long list of UNCOMPENSATED Promotions put out about AMBS's Awesome company and potential success!!
Find something negative worth looking at (with links)!! Good Luck!!
Go AMBS!!!!!!!!!!
Did you tell him how supportive you are for his company??
$BMSN News IND submitted...
Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I(TM) Stem Cell Drug for Aplastic
Regen BioPharma a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company's HemaXellerate Iâ„¢ stem cell drug in patients with drug-refractory aplastic anemia.
HemaXellerate Iâ„¢ is a patient-specific composition of cells that have previously been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies. The company, together with an internationally-renowned group of stem cell researchers, recently published the scientific basis for the HemaXellerate Iâ„¢ product which may be found at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf.
"Currently patients with aplastic anemia who are resistant to drugs and ineligible for bone marrow transplant have no therapeutic options. We are fortunate to be in the position to have developed a novel approach to potentially treat this terrible condition," said David Koos, CEO of Bio-Matrix. "To our knowledge the HemaXellerate Iâ„¢ product is the only therapy that has potential to simultaneously block the underlying cause of aplastic anemia while at the same time rebuilding the bone marrow tissue that has been damaged by the disease."
If the clinical trial is successful, the company plans to expand use of HemaXellerate Iâ„¢ to other conditions associated with bone marrow dysfunction, with the overall goal of entering the hematopoietic growth factor market. This market is substantial in size and currently includes drugs such as Neupogen®, Neulasta®, Leukine® and Revolade®.
"Current drug-based approaches for healing bone marrow damage involve "flooding" the body with growth factors, which is extremely expensive and causes unintended consequences because of lack of selectivity," said Dr. Vladimir Bogin, CEO of Chromos Pharma (a contract research organization), which collaborated with Regen on filing the IND and member of the Company's Scientific Advisory Board. "Based on our data HemaXellerate Iâ„¢ possesses the advantage delivering an optimized cellular mixture that produces the needed growth factors at the specific location in the bone marrow niche."
The planned clinical trial anticipates recruiting 10 patients who have failed standard of care, which will be treated with HemaXellerate Iâ„¢ and followed for safety parameters and signals of efficacy. Therapeutic effects will be quantified based on immunological measurements, as well as improvement in blood counts. Patients in the trial will be assessed for one year, however, because the trial is unblinded, data will be available as the study progresses.
$ENTB Could see some movement...
News just released on BMSN
Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I(TM) Stem Cell Drug for Aplastic
Regen BioPharma a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company's HemaXellerate Iâ„¢ stem cell drug in patients with drug-refractory aplastic anemia.
HemaXellerate Iâ„¢ is a patient-specific composition of cells that have previously been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies. The company, together with an internationally-renowned group of stem cell researchers, recently published the scientific basis for the HemaXellerate Iâ„¢ product which may be found at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf.
"Currently patients with aplastic anemia who are resistant to drugs and ineligible for bone marrow transplant have no therapeutic options. We are fortunate to be in the position to have developed a novel approach to potentially treat this terrible condition," said David Koos, CEO of Bio-Matrix. "To our knowledge the HemaXellerate Iâ„¢ product is the only therapy that has potential to simultaneously block the underlying cause of aplastic anemia while at the same time rebuilding the bone marrow tissue that has been damaged by the disease."
If the clinical trial is successful, the company plans to expand use of HemaXellerate Iâ„¢ to other conditions associated with bone marrow dysfunction, with the overall goal of entering the hematopoietic growth factor market. This market is substantial in size and currently includes drugs such as Neupogen®, Neulasta®, Leukine® and Revolade®.
"Current drug-based approaches for healing bone marrow damage involve "flooding" the body with growth factors, which is extremely expensive and causes unintended consequences because of lack of selectivity," said Dr. Vladimir Bogin, CEO of Chromos Pharma (a contract research organization), which collaborated with Regen on filing the IND and member of the Company's Scientific Advisory Board. "Based on our data HemaXellerate Iâ„¢ possesses the advantage delivering an optimized cellular mixture that produces the needed growth factors at the specific location in the bone marrow niche."
The planned clinical trial anticipates recruiting 10 patients who have failed standard of care, which will be treated with HemaXellerate Iâ„¢ and followed for safety parameters and signals of efficacy. Therapeutic effects will be quantified based on immunological measurements, as well as improvement in blood counts. Patients in the trial will be assessed for one year, however, because the trial is unblinded, data will be available as the study progresses.
$RIGH Breaking out... .0002's are gone 91M volume
I know...I can't wait! Been here since I bought in at .001 Sold enough off in the .003's to recoup my investment with a small profit...rest are free shares sitting and waiting for the train ride. I'll probably hold them indef. Even if it were to drop to .0001, I will still receive a profit...not a large one though! Lol
I haven't decided to get into this stock yet, so I'm not sure what you're referring to.
I've read enough stock news letters to recognize that the 'fictional characters' and 'entertainment' references are NOT typical.
They're tellin you flat out that you could be taken for an idiot if you believe their fictional conversations and if you don't understand that they're trying ot entertain......someone.
And i don't see anyone having a coronary but yourself over being challenged for falling for nonsense!
Exactly...just like any other newsletter that sends out predictions on a stock! You decide for yourself if it is viable or not in making your decision to buy or not; to sell or hold!!
It's not something to have a corinary over because someone is posting predictions from another source. OMG!! Especially coming from someone that was all for BMSN not too long ago, who suddenly seems to be against it now. But still is all for BMSN's sister company...same freaking company!!
Furthermore...what I meant by my comment of
(Site prediction/forecast creditability is unknown to me)
It's called a rumor...a prediction! Last I knew, that is how the ups and downs work in the stock market as a whole...not just pennies! Buy on the rumor; sell on the news!! News confirms or denies the rumors.
Hell even WalL Street and other market analyst put out company predictions that aren't always correct when the "news" comes out...does that make them liars also!!
duelittle...
Here are the links (Site prediction/forecast creditability is unknown to me) that PeterGates is referring:
http://biotechnewsstockreview.blogspot.com/2013/02/hot-biotech-stocks-news-ambs-bmsn-ctix.html
http://biotechnewsstockreview.blogspot.com/2013/01/roche-talking-to-bio-matrix-scientific.html
Where is this "list" of chilled stocks you are referring too? Where is the website that holds this up to date maintained current updated list? Do not mention BigBlake's list...it is manually tracked and updated by him on his board.
E-Trade told me it wasn't on DTC Chill either.
This link is to a PDF file, which is not a living document (updates as changes occur), the list at the bottom of the iHub post is a manually maintained and updated listing by, I'm assuming, BigBlake1, since the same list is posted on the board he maintains. So can anyone provide a search list that provides live data maintained by reputable agency??
Doht!! My bad! Wrong board! I some how crossed over between L2 for another .0001 onto this board. I have shares in SUGO @ .0001 and the one I thought I on the board of. LOL
I don't get what you are saying...there are plenty of .0001s up for grabs, so buy them all up!! What's stopping you??
Great news...do you have a link??
LOL TOO FUNNY!!!
Then why are you here...an attempt to save us!! I'm sure there is other motive involved!
$BMSN @ .004 I've been riding this one since end of December from Trader's pick list. Riding this with free shares...Thanks Trader!!
$BMSN Fasten your seatbelts away we go!!
$INAR .0001
Trader, what are your thoughts on INAR.
0.0000 bid; 0.0001 ask; today's vol = 247,217,498 so far today.
News release today of 1B buy back. No current plans for R/S
InternetArray Announces Up to One Billion Share Buyback and Enters $50 Billion Southeast Asia Social Media Network Market wit...
Shares Outstanding 3,418,271,060 a/o Sep 30, 2012
Float 167,638,032 a/o Dec 31, 2011
Authorized Shares 19,900,000,000 a/o Jun 30, 2012
I bought my son a new laptop with Windows 8 on it for christmas. I had to use his laptop while mine was in the shop last week. I'll stick to my Windows 7. I absolutely HATE Windows 8!
Lol I know Right!!
Go BMSN
Thank you for your concern and coming to this board and many other boards just to save us!! Thank you!!!
Think about it...If this was only a shell, why would the govt even consider bailing this out if it had no value!!
Thank you for your concern!!
If you believe in MM Signals, this is what they mean...
Market Maker Signals on Level ll
007 - Accumulated shares
100 - I need shares.
200 - I need shares badly,but do not take the stock down.
300 - Take the price down so I can load shares
400 - Keep trading it sideways.
500 - Gap the stock. This gap can be either up or down, depending on the direction of the 500 signal.
505 - Short on Shares
911 - Pending News
999 - Fake Wall
Unfortunatley, it only ended up being a temp fix...They relisted AMBS on the Berlin market again after the CUSIP change.
If you will notice, the ones that were paid promos were paid by a third party!!
Thank you for your concern!!
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.
(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached, if applicable.
Paul...It clearly states "will be filed on or before the fifteenth calendar day following the prescribed due date"
And they have 15 days from the last day of the quarter to file...thus being 15th day of the month for the previous quarter (15 Jan, in this case), plus a 15 day extension per their 31 Dec filing. If I'm not mistaking...that puts it due 30 Jan 2012!! Pretty much a no brainer!!
Gerald bought!! Reread the news release.